Skip to main content

Key-LARGO: A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients with Gastro-esophageal Cancer,"

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

November 14, 2017

End Date

October 31, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

November 14, 2017

End Date

October 31, 2022